-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization

PUBT·11/15/2026 10:30:54
Listen to the news
Hansoh's Aumolertinib Wins EMA Panel Backing for EU Marketing Authorization
  • The European Medicines Agency's CHMP recommended EU marketing authorization for Hansoh Pharmaceutical's aumolertinib on November 12, 2026.
  • The drug, marketed as Aumseqa outside China, is intended to treat non-small cell lung cancer.
  • Marketing authorization remains subject to final European Commission approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261115-12413057), on November 15, 2026, and is solely responsible for the information contained therein.